Semaglutide before and after: what the results really look like

Average weight loss in the STEP 1 trial was around 15% over 68 weeks at the 2.4mg maintenance dose — but individual results ranged widely above and below that figure.
Results depend heavily on dose, duration, consistency, and how closely the lifestyle changes are followed alongside treatment.
Semaglutide works by mimicking GLP-1, a gut hormone that reduces appetite and slows gastric emptying, the biology varies from person to person.
The higher 7.2mg dose, approved by the MHRA in January 2026, has shown around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide.

In clinical trials, adults taking semaglutide 2.4mg (Wegovy) lost an average of around 15% of their body weight over 68 weeks alongside a reduced-calorie diet and activity changes — that figure comes from the STEP 1 trial, published in the New England Journal of Medicine. Before-and-after semaglutide results vary considerably between individuals, and understanding why is more useful than any single number. These are prescription-only medicines; a GPhC-registered prescriber assesses whether they are clinically appropriate before treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Why before-and-after semaglutide results differ so much, and what the trial data tells us

The biggest misconception: before-and-after photos tell you what semaglutide does to one person, not what it will do for you

It's completely understandable to search for before-and-after pictures. You want to know whether this is real, whether it works, and whether it would work for you. That instinct makes sense. The difficulty is that individual transformations (however striking) are the least informative evidence available, because they are selected and they represent one body's response to one treatment at one dose over one timeframe.

What is far more useful is the trial data, and those numbers are genuinely impressive. In STEP 1, nearly 2,000 adults without diabetes took semaglutide 2.4mg weekly for 68 weeks. The average weight reduction was around 15%. Roughly one in three participants lost more than 20% of their starting weight. A meaningful proportion lost less than 10%. That spread is the honest picture of semaglutide before and after results, not a single outcome, but a distribution.

The factors that shape where you land in that distribution include your starting weight, how well you tolerate dose increases, how consistently you follow lifestyle changes alongside treatment, whether you have conditions that affect metabolism, and how long you stay on treatment. No photograph shows you any of those variables.

How results change across the first weeks, months and beyond

Semaglutide weight loss before and after looks very different at one month versus six months versus a year. The treatment starts at a low dose (0.25mg weekly) specifically to allow your body to adjust, this is not the dose at which meaningful weight loss is expected. Titration happens gradually, with many people reaching the 2.4mg maintenance dose around the five-month mark.

Most people notice appetite changes fairly early. Actual weight loss tends to follow. Early results at the four-week mark are usually modest; the picture at one month is typically just the beginning of the trajectory. By two months, dose increases have usually begun and changes become more visible. By three months, many people are approaching or at higher doses, and results tend to become more consistent.

The steepest weight loss generally happens in the first six months. Progress slows after that, which is normal and expected, not a sign that treatment has stopped working. The STEP 1 trial ran for 68 weeks, and participants continued to see benefit across that full period at the maintenance dose.

Does it work differently for men and women?

The short answer is: broadly similar mechanisms, some differences in practice. Men starting from a higher absolute body weight can see larger absolute weight losses even at similar percentage reductions. The semaglutide results in men page covers this in more detail, but the clinical trials showed the drug works across sexes, and STEP 1 included both.

Body composition changes matter here too. A separate trial (the BELIEVE study) looked at combining semaglutide with bimagrumab, an agent that targets muscle loss during weight reduction. The BELIEVE trial results from 2025 are worth reading if you're thinking carefully about what the weight you lose is made of. Preserving lean mass while losing fat is a genuine consideration for anyone on long-term treatment, and something a prescriber can factor into advice around resistance activity and protein intake.

What the newer 7.2mg dose adds, and how it compares

Since January 2026, the MHRA has approved semaglutide at a higher maintenance dose of 7.2mg weekly. Trials at this dose reported around 20.7% average weight loss over 72 weeks, a meaningful step up from the 2.4mg results and one that brings semaglutide closer to the outcomes seen with tirzepatide (Mounjaro) in trials. The MHRA approved a dedicated single-dose 7.2mg pen in April 2026, as announced on GOV.UK. This dose is licensed for adults with a BMI of 30 or above; titration still begins at 0.25mg and increases are made by the prescriber.

If you're weighing up Wegovy against other options, the Wegovy before-and-after page covers the full picture for the injection, and the Wegovy overview explains how the treatment works in detail. Understanding how long Wegovy takes to work is worth reading before you set expectations for your own timeline. For anyone thinking about the cost side, the Wegovy cost page sets out what private treatment typically involves in the UK.

Semaglutide is a prescription-only medicine. A clinician reviews your health, weight history and any other medicines before deciding whether it's suitable and at what dose to begin. If you'd like that assessment, you can start your free consultation with our prescribers, the same day, with no waiting list.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions